Dr. West on FDA Approval of Brigatinib in ALK+ NSCLC

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of brigatinib (Alunbrig) as a treatment for patients with metastatic ALK-positive non–small cell lung cancer (NSCLC) who are resistant to prior crizotinib (Xalkori).

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of brigatinib (Alunbrig) as a treatment for patients with metastatic ALK-positive non—small cell lung cancer (NSCLC) who are resistant to prior crizotinib (Xalkori).

Related Content:

OncLive TVLung Cancer
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma
Subcutaneous Pembrolizumab Plus Chemo Meets Pharmacokinetic End Points in NSCLC